Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Collectively, as well as independently, the firms represent generations of commercial real estate experience and family ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...